与BRAF和MEK抑制剂相关的皮肤不良事件:系统性审查和元分析
Junhui Qian1, Jinlong Wan2, Qin Yao1
1Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, China.
Frontiers in pharmacology
|January 8, 2025
概括
与BRAF抑制剂单独治疗相比,用于黑色素瘤的BRAF和MEK抑制剂联合治疗显示皮肤不良事件 (CAE) 的风险较低. 这包括减少皮疹,脱发和皮肤癌的发病率,有助于治疗的利益风险平衡.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮肤不良事件 (CAE) 是与黑色素瘤的BRAF和MEK抑制剂疗法相关的常见并发症.
- 描述组合治疗与单一治疗的特定风险对于优化患者管理和治疗决策至关重要.
研究的目的:
- 为了比较使用联合BRAF和MEK抑制剂治疗的黑色素瘤患者中CAE的发生率,与仅使用BRAF抑制剂治疗的患者进行比较.
- 为了确定两种治疗方案之间风险差异的特定CAE.
主要方法:
- 进行了系统的文献审查和随机临床试验的元分析.
- 来自PubMed,Cochrane,Embase和Web of Science的数据进行了综合,重点是比较BRAF和MEK抑制剂与BRAF抑制剂单一治疗的试验.
- 对各种CAE计算了聚合风险比率 (RRs) 和95%置信区间 (CI),包括皮疹,脱发和皮肤瘤.
主要成果:
- 与BRAF抑制剂单独治疗相比,联合BRAF和MEK抑制剂治疗与多种CAE的风险明显降低.
- 观察到皮疹 (RR,0.73),脱发 (RR,0.28),皮症 (RR,0.30) 和皮肤状细胞癌 (RR,0.21) 的风险具体降低.
- 在两个治疗组之间,光敏反应的风险是可比的.
结论:
- 与BRAF抑制剂单独治疗相比,BRAF和MEK抑制剂组合治疗在黑色素瘤患者中提供了有利的CAE安全概况.
- 这些发现支持一种平衡的方法,权衡黑色素瘤治疗的疗效与潜在的皮肤副作用.
- 进一步的研究可能会完善管理策略,以减轻CAE,同时最大限度地提高治疗效益.
更多相关视频
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
2.9K
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
945
相关概念视频
MAPK Signaling Cascades
5.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.2K
Skin Cancer
3.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.1K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
